Hengrui Pharmaceuticals' Development Capabilities Undervalued -- Market Talk

Dow Jones05-15

1009 GMT - Hengrui Pharmaceuticals' research and development and business development capabilities remain undervalued, HSBC researchers say in a note. They highlight the value of Hengrui's recent $15.2 billion deal with Bristol Myer-Squibb exceeded its deal with GSK last year, reflecting broad recognition of Hengrui's R&D capabilities and efficiency. The drugmaker's strong clinical pipeline and efficient drug discovery platform should support a recurring business development model and create additional collaboration opportunities. HSBC maintains its 2026 results forecasts but raises its 2027-2028 revenue and net profit estimates as well as its R&D costs projections. Industry-wise, Chinese drugmakers are likely to continue securing business development deals with multinational pharmaceutical companies despite geopolitical risks, supported by high efficiency, lower R&D costs and improving data transparency. Hengrui's H-shares last closed at HK$65.75. (jason.chau@wsj.com)

(END) Dow Jones Newswires

May 15, 2026 06:09 ET (10:09 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2635882430?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-15 18:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635882430","market":"fut","top_or_hot":-1,"title":"Hengrui Pharmaceuticals' Development Capabilities Undervalued -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1009 GMT - Hengrui Pharmaceuticals' research and development and business development capabilities remain undervalued, <a href=\"https://laohu8.com/S/HSBC\">HSBC</a> researchers say in a note. They highlight the value of Hengrui's recent $15.2 billion deal with Bristol Myer-Squibb exceeded its deal with GSK last year, reflecting broad recognition of Hengrui's R&amp;D capabilities and efficiency. The drugmaker's strong clinical pipeline and efficient drug discovery platform should support a recurring business development model and create additional collaboration opportunities. HSBC maintains its 2026 results forecasts but raises its 2027-2028 revenue and net profit estimates as well as its R&amp;D costs projections. Industry-wise, Chinese drugmakers are likely to continue securing business development deals with multinational pharmaceutical companies despite geopolitical risks, supported by high efficiency, lower R&amp;D costs and improving data transparency. Hengrui's H-shares last closed at HK$65.75. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 15, 2026 06:09 ET (10:09 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hengrui Pharmaceuticals' Development Capabilities Undervalued -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHengrui Pharmaceuticals' Development Capabilities Undervalued -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-15 18:09</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1009 GMT - Hengrui Pharmaceuticals' research and development and business development capabilities remain undervalued, <a href=\"https://laohu8.com/S/HSBC\">HSBC</a> researchers say in a note. They highlight the value of Hengrui's recent $15.2 billion deal with Bristol Myer-Squibb exceeded its deal with GSK last year, reflecting broad recognition of Hengrui's R&amp;D capabilities and efficiency. The drugmaker's strong clinical pipeline and efficient drug discovery platform should support a recurring business development model and create additional collaboration opportunities. HSBC maintains its 2026 results forecasts but raises its 2027-2028 revenue and net profit estimates as well as its R&amp;D costs projections. Industry-wise, Chinese drugmakers are likely to continue securing business development deals with multinational pharmaceutical companies despite geopolitical risks, supported by high efficiency, lower R&amp;D costs and improving data transparency. Hengrui's H-shares last closed at HK$65.75. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 15, 2026 06:09 ET (10:09 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1146622755.USD","symbol_name":"安本中国A股股票基金A Acc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2635882430","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635882430","pubTimestamp":1778839740,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1009 GMT - Hengrui Pharmaceuticals' research and development and business development capabilities remain undervalued, HSBC researchers say in a note. They highlight the value of Hengrui's recent $15.2 billion deal with Bristol Myer-Squibb exceeded its deal with GSK last year, reflecting broad recognition of Hengrui's R&D capabilities and efficiency. The drugmaker's strong clinical pipeline and efficient drug discovery platform should support a recurring business development model and create additional collaboration opportunities. HSBC maintains its 2026 results forecasts but raises its 2027-2028 revenue and net profit estimates as well as its R&D costs projections. Industry-wise, Chinese drugmakers are likely to continue securing business development deals with multinational pharmaceutical companies despite geopolitical risks, supported by high efficiency, lower R&D costs and improving data transparency. Hengrui's H-shares last closed at HK$65.75. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600276":"恒瑞医药","LU1146622755.USD":"安本中国A股股票基金A Acc","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","BK0239":"医药制造","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","HSBH":"HSBC Holdings plc ADRhedged","BK4521":"英国银行股","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","LU0211326839.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) INC","BK0183":"MSCI概念","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","BK4588":"碎股","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU0496365809.HKD":"TEMPLETON GLOBAL INCOME \"A\" (HKD) INC (Q)","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","BK0188":"融资融券","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","BK0012":"证金概念","LU0211326755.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) ACC","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU1997245177.USD":"安联神洲A股基金","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK0028":"国家队","HSBC":"汇丰","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","BK4207":"综合性银行","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0976567544.SGD":"FTIF - Templeton Global Income A Mdis SGD-H1","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","BK0060":"抗癌","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","BK4585":"ETF&股票定投概念","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","BK0196":"行业龙头","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A"},"translate_title":"恒瑞医药开发能力被低估--市场谈","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":0.9,"HSBH":0.6,"HSBC":0.7},"content_text":"1009 GMT - Hengrui Pharmaceuticals' research and development and business development capabilities remain undervalued, HSBC researchers say in a note. They highlight the value of Hengrui's recent $15.2 billion deal with Bristol Myer-Squibb exceeded its deal with GSK last year, reflecting broad recognition of Hengrui's R&D capabilities and efficiency. The drugmaker's strong clinical pipeline and efficient drug discovery platform should support a recurring business development model and create additional collaboration opportunities. HSBC maintains its 2026 results forecasts but raises its 2027-2028 revenue and net profit estimates as well as its R&D costs projections. Industry-wise, Chinese drugmakers are likely to continue securing business development deals with multinational pharmaceutical companies despite geopolitical risks, supported by high efficiency, lower R&D costs and improving data transparency. Hengrui's H-shares last closed at HK$65.75. (jason.chau@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 15, 2026 06:09 ET (10:09 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2635882430","isCrawlerRequest":true}